Hepatitis C News and Research

Latest Hepatitis C News and Research

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Unilife Corporation today announced it has received from the U.S. Food and Drug Administration 510(k) market clearance for the Unitract™ 1mL Insulin Syringes assembled at its Lewisberry, PA manufacturing facility.

6 Apr 2010

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Peregrine Pharmaceuticals, Inc. today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine.

5 Apr 2010

Request for lift of full clinical hold on Proellex program

Repros Therapeutics Inc. today announced that the Company has requested a lift of the full clinical hold on its oral drug Proellex® being developed for the treatment of uterine fibroids and endometriosis. On August 4, 2009, the FDA noted that further testing of Proellex® was placed on full clinical hold due to findings of serious adverse events associated with liver toxicity.

5 Apr 2010

MinuteClinic launches health condition monitoring services for diabetes, asthma and high cholesterol patients

MinuteClinic, the largest provider of retail-based medical clinics in the United States, has introduced a series of convenient health condition monitoring services to help patients previously diagnosed with diabetes, asthma, high cholesterol and high blood pressure overcome the challenges of living with their conditions. Health condition monitoring is available at MinuteClinic locations in CVS/pharmacy stores in 20 states and the District of Columbia. MinuteClinic is the retail health care division of CVS Caremark (CVS).

2 Apr 2010

Hepatitis C infected donor kidneys thrown away despite urgent need

More than half of donor kidneys in the United State infected with hepatitis C are thrown away, despite the need among hepatitis C patients who may die waiting for an infection-free organ, Johns Hopkins research suggests.

2 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

Liver function tests misinterpreted in majority of children's hospitals

New research led by physician-scientists at University of California, San Diego School of Medicine shows that the test most commonly used to screen pediatric patients for chronic liver disease is often incorrectly interpreted in many children's hospitals throughout the United States.

2 Apr 2010

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, today announced its 2009 year-end financial results.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the fourth quarter and full year ended December 31, 2009.

31 Mar 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Study finds rapid epidemiological shift in HAV infection in Korea

In Korea, there has been a rapid epidemiological shift in hepatitis A virus infection as a result of rapid economic development. The adult cases of acute hepatitis A have increased rapidly during the past 10 years due to the emergence of susceptible adults in Korea.

31 Mar 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

GSK offers free vaccines for low income adults without insurance coverage

GlaxoSmithKline today announced the launch of the GSK Vaccines Access Program, which will provide the company's adult vaccines free of charge to eligible, low income individuals who do not have insurance coverage for vaccines. The program will cover the company's FDA-approved vaccines for Hepatitis A, Hepatitis B, tetanus, diphtheria, and pertussis for eligible persons ages 19 and older.

29 Mar 2010

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

CVS/pharmacy announced today that it will collect expired or unused medications from the public at two collection events in Rhode Island to be held at stores in the town of Coventry and the city of Cranston in April.

27 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Unilife's Unitract 1mL Insulin Syringes receive 510(k) market clearance

Peregrine's PS-targeting antibodies block HIV from entry into blood cells

Request for lift of full clinical hold on Proellex program

MinuteClinic launches health condition monitoring services for diabetes, asthma and high cholesterol patients

Hepatitis C infected donor kidneys thrown away despite urgent need

2010 DDW conference to highlight breakthrough research on GI health

Liver function tests misinterpreted in majority of children's hospitals

Biostar Pharmaceuticals fiscal 2009 revenues up 57.2%

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

IVAX Diagnostics reports net revenue of $4.5M for quarter ended December 31, 2009

T-cell cytolytic activity may be effective in clearing HBV infection

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

PhRMA report: 234 medicines in development for special health care needs of children

Study finds rapid epidemiological shift in HAV infection in Korea

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Praxis extends patient recruitment services for international HCV study

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Potential new target for treating HCV infection

GSK offers free vaccines for low income adults without insurance coverage

CVS/pharmacy to help consumers dispose unwanted medication in an effort to protect the environment

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in